VentriPoint Diagnostics Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $26.66 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
VentriPoint Diagnostics Ltd had its IPO on under the ticker symbol VPTDF.
The company operates in the Healthcare sector and Medical Devices industry. VentriPoint Diagnostics Ltd has a staff strength of 0 employees.
Shares of VentriPoint Diagnostics Ltd opened at $0.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.14 - $0.17, and closed at $0.17.
This is a -2.35% slip from the previous day's closing price.
A total volume of 118,710 shares were traded at the close of the day’s session.
In the last one week, shares of VentriPoint Diagnostics Ltd have slipped by -10.42%.
VentriPoint Diagnostics Ltd's Key Ratios
VentriPoint Diagnostics Ltd has a market cap of $26.66 million, indicating a price to book ratio of 8.2705 and a price to sales ratio of 897.0447.
In the last 12-months VentriPoint Diagnostics Ltd’s revenue was $51348 with a gross profit of $-6268 and an EBITDA of $-5038146. The EBITDA ratio measures VentriPoint Diagnostics Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, VentriPoint Diagnostics Ltd’s operating margin was -9827.93% while its return on assets stood at -54.66% with a return of equity of -113.24%.
In Q2, VentriPoint Diagnostics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 84.2%.
VentriPoint Diagnostics Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VentriPoint Diagnostics Ltd’s profitability.
VentriPoint Diagnostics Ltd stock is trading at a EV to sales ratio of 705.6483 and a EV to EBITDA ratio of -5.8498. Its price to sales ratio in the trailing 12-months stood at 897.0447.
VentriPoint Diagnostics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.89 million
- Total Liabilities
- $1.17 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
VentriPoint Diagnostics Ltd ended 2023 with $3.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.89 million while shareholder equity stood at $2.39 million.
VentriPoint Diagnostics Ltd ended 2023 with $0 in deferred long-term liabilities, $1.17 million in other current liabilities, in common stock, $-51081550.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.31 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $82959.00.
VentriPoint Diagnostics Ltd’s total current assets stands at $3.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $13686.00 compared to accounts payable of $835173.00 and inventory worth $0.
In 2023, VentriPoint Diagnostics Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, VentriPoint Diagnostics Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
VentriPoint Diagnostics Ltd stock is currently trading at $0.17 per share. It touched a 52-week high of $0.255 and a 52-week low of $0.255. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.2 and 200-day moving average was $0.18 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 175% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About VentriPoint Diagnostics Ltd
Similar Industry Stocks (Medical Devices)
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity of chemotherapy treatments for cancer, and Covid-19 related heart issues. The company was incorporated in 2005 and is headquartered in Toronto, Canada.